

Pharmacotherapeutics

녹내장의 약물치료

Medical Treatment of Glaucoma

28

Ki Ho Park, M.D.

Department of Ophthalmology

Seoul National University College of Medicine & Hospital

E-mail : kihopark@snu.ac.kr

Abstract

Most types of glaucoma do not present their symptoms until the advanced stage. Thus early detection is critical for the best outcome of treatment in glaucoma and is possible by routine ocular examinations or routine health check - up. Once glaucoma is suspected, diagnostic work - up should be performed including evaluation of the optic nerve head and retinal nerve fiber layer and visual field examinations. Treatment of glaucoma is focused to lower the intraocular pressure(IOP) that serves as the most important risk factor of glaucoma. Setting a target pressure before initiation of IOP - lowering therapy is important. Medication should be selected in consideration of the efficacy, mode of action, and side effects of agents along with patient compliance. In addition to IOP - lowering therapy, possible systemic vascular problems should be evaluated and managed. The treatment outcome should be followed by measurement of IOP, evaluation of optic nerve head and RNFL, and visual field examinations.

Keywords : Glaucoma; Intraocular pressure(IOP);

Optic nerve head;

Retinal nerve fiber layer(RNFL);

Visual field

: ; ; ; ; ;

3
90~100
가

2%

가

가

가


가

가

()

(

).



1. (A) 0.5, 0.4

(B)
(C)

0.4

가 3

가

가

2001



2,323

가

가 , , ,
 , 가 (3).
 가 (1, 2).

13%

190



2. (A, C)

(B, D)

(A, B)

(C, D)

(D),

(B)


(tubular vision)


10~21mmHg

가

가

(cup)가






Pharmacotherapeutics


6
18mmHg
가가 12mmHg
(4). 30%
(1). 5 가 80%
(2). (5). 40%
가 가 20% 가
가 , ,
(가)
가 , 2 , ,
1.

timolol, car-
teolol, levobunolol, befunolol, betaxolol
가 20~25%

1 betaxolol

가





가

가 가

가

25~30%

가

Latanoprost, travoprost, bimatoprost

, unoprostone

가

가

가

Acetazolamide, methazolamide, dichlorphenamide

가

2

acetazolamide

20~25%

Apraclonidine bri-

, , ,

Meth-

monidine 가 가 brimonidine

brimoni-

, , ,

가

zolamide

가

Stevens - Johnson

. 가

, , 10%

2~3

mannitol

dorzolamide brinzolamide

glycerol

15~20%

가

2~3

2.

pilocarpine

가


가


()

20~25%

2


가






Pharmacotherapeutics

- 15mmHg
30%
- 가 A, B 가 25% 가 10.5mmHg 가 20%, 30% 40%
- 50%
30~35%
가
가
(fixed combination therapy)
Timolol + dorzolamide,
Latanoprost + timolol
- 4.
- 1~3 가 가
가
3. 가
가
1~2
가
2~4
가
5.
가
가
30mmHg 30%
21mmHg





가

6.

가

(calcium channel
blocker) (vasospasm)
가

가

2

가 가

가

가

NMDA(N-methyl D-Aspartate)
, glutamate 가 exitotoxic
pathway memantin 가

가 ginkgo biloba extract

가


heat 가


shock protein

betaxolol brimonidine
in vitro

가

가





S27 - 42

- 가
- 가
1. 3 . . : , 2003
2. Hayreh SS. The role of age and cardiovascular disease in glaucomatous optic neuropathy. Surv Ophthalmol 1999; 43(Suppl 1):
3. Park KH, Kim YY, Hong C. The Angle - Closure Glaucoma Update 2002. Seoul: New Medical Publications, 2003
4. The AGIS Investigators. The Advanced Glaucoma Intervention Study(AGIS): 7. The Relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429 - 40
5. Collaborative Normal - Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal - tension glaucoma. Am J Ophthalmol 1998; 126: 498 - 505

가

가

* : 3 , 5 , 1 , 2
* () : 2 , 5 , 1
* :

가 : [140 - 721] 1 302 - 75
Tel. 02-794-2480, 6587, 2474(ARS 8) Fax. 02-792-1361
`:` `/`

대한의사협회